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ABSTRACT 
 Crohn’s disease is a chronic inflammatory disease of the intestinal tract that results from a 
loss of tolerance to the enteric microbiota. Previous studies have established that interleukin (IL)-
10 is an important anti-inflammatory cytokine driving intestinal macrophage (IM) tolerance. 
Within a cell, transcriptional responses are governed by transcription factors binding of accessible, 
nucleosome-free regions of DNA. Previously published studies have shown that marked changes 
in chromatin accessibility occur in IMs isolated from colitis-prone Il10-/- mice. Interestingly, 
addition of ectopic IL-10 to Il10-/- mice did not recover chromatin accessibility changes in 95% of 
the regions identified, suggesting that these chromatin accessibility changes were stable. We 
hypothesized that the stable chromatin landscape of Il10-/- macrophages may be altered using small 
molecule inhibitors of chromatin modifying proteins resulting in the restitution of IM tolerance to 
the enteric microbiota. A high-throughput screen with a chromatin accessibility readout was used 
to test small molecule inhibitors of chromatin modifying enzymes in Il10-/- macrophages. Changes 
in chromatin accessibility were assessed using a relative chromatin inhibition (RCI) score which 
compares accessibility changes at two regions that are only accessible in Il10-/- macrophages and 
two control regions. This screen identified several bromodomain inhibitors, including (+)-JQ1, 
that have the ability to decrease relative chromatin accessibility. Subsequent testing using (+)-JQ1 
revealed that (+)-JQ1 attenuates mRNA levels of inflammatory Il6 and Il12ß in lipopolysaccharide 
(LPS)-stimulated Il10-/- macrophages. We conclude that bromodomain inhibitors decrease 







Crohn’s disease (CD) is a chronic inflammatory disease that affects the entire digestive 
system.1 As many as 90% of patients require surgery at some point throughout the course of their 
disease, necessitating further research to understand the underlying factors that contribute to 
disease pathogenesis and progression.2,3 Previous studies have identified single nucleotide 
polymorphisms that are associated with a higher risk of developing CD or associated with certain 
disease characteristics.4,5 Many of these variants have been located in close proximity to genes that 
are known to be expressed by macrophages, a key innate immune cell type. Macrophages are 
primarily responsible for removing foreign antigens and debris from the body and also recruiting 
adaptive immune cells.6,7 Intestinal macrophages (IMs) are unique in that they are able to carry 
out strong phagocytic responses to bacteria without promoting inflammation.8 However, in CD 
patients, IM function is altered as they have gained the ability to secrete pro-inflammatory 
cytokines and recruit T helper (Th) 1- and Th17-based responses, which eventually leads to 
destruction of the intestinal epithelium; however, the changes in the IM program that are associated 
with these functional changes have yet to be defined.9  
DNA is wrapped around histone proteins to form chromatin, allowing the entire genome 
to fit in the nucleus.10 Regions devoid of nucleosomes (accessible chromatin) are known to contain 
regulatory elements, such as promoters and enhancers, which have a downstream effect of gene 
expression. Previous studies have examined changes in chromatin accessibility in IMs from IL-10 
knock-out (Il10-/-) mice, a colitis prone mouse model that is dependent on the presence of bacteria 
and develops colitis through macrophage and Th1 and Th17 activation.4 In this study, 
Formaldehyde-Assisted Isolation of Regulatory Elements using sequencing (FAIRE-seq) was used 
to demonstrate that loss of IL-10 leads to genome-wide changes in chromatin accessibility, where 
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accessibility is increased at many key genes associated with inflammatory pathways (referred to 
as IL-10 Variable Accessible Regions or IL10VARs).4 This chromatin accessibility profile was 
observed in IMs isolated from germ-free Il10-/- mice, and largely resembles peripheral 
macrophages responding to a bacterial stimulus, suggesting that the Il10-/- IMs are predisposed 
toward an inflammatory profile. Addition of ectopic IL-10 to adult Il10-/- mice does not revert the 
chromatin accessibility, indicating that this chromatin profile is stable.4 If the chromatin profile is 
stable, is there a compound or experimental condition that could alter the chromatin profile to its 
previous accessibility?  
 Our study identifies a small molecule inhibitor of chromatin modifying proteins,  
(+)-JQ1, that can alter regions of chromatin that show increased accessibility in Il10-/- mice. 
Because of the chromatin accessibility alteration as a result of (+)-JQ1, genes for pro-inflammatory 
cytokines are transcribed in different amounts. These data indicate that small molecule inhibitors 
of chromatin modifying proteins can alter chromatin accessibility at specific loci. By lessening 
pro-inflammatory cytokine secretions, (+)-JQ1 is able to attenuate inflammation and has potential 











MATERIALS AND METHODS 
 
Figure 1. Graphical outline of experimental pathways 
IL-10VARs were established, macrophages were incubated with chromatin modifying enzymes 
and analyzed at the previously identified Il10VARs, and subsequently a promising screen 
molecule was studied more in depth. 
Mice 
 Mice were housed, raised and handled in accordance with the guidelines from the 
American Association for Laboratory Animal Care and Research Protocols, and the Institutional 
Animal Care and Use Committee of the UNC approved experiments (IACUC #15-280.0).4 Four 
mice were used in the chromatin modifying enzyme screen each of a C57BL/6 background. WT 
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and Il10-/- mice, conserved of age between 8 and 10 weeks were used. Mice were euthanized by 
CO2 inhalation followed by cervical dislocation. All mice work was done by DLAM approved 
personnel. 
BMDM Culture 
 BMDM’s we cultured as previously described.11 Isolated tibia and femur bones were 
flushed with wash media (RPMI-1640, 1% PCN-Strep, Gibco) to isolate bone marrow. Bone 
marrow cells were physically strained through a 70μm cell strainer and red blood cells were 
removed with Lysis Buffer (8.3g NH4Cl, 1.0g KHCO3, 0.1mM EDTA in 1L dH2O) at room 
temperature (RT). The reaction was stopped with complete media (RPMI-1640, 1% PCN-Strep, 
10% FBS, Gibco), and centrifuged. Cells were washed, counted and resuspended at a concentration 
of 1 million cells/mL in complete media containing M-CSF (1:10 dilution). Additional complete 
media containing M-CSF was added on day 3. After 6 days of incubation at 37°C and 5% CO2, 
supernatant was removed, cells were removed from the plate with TrypLE (2mL), followed by 
centrifugation. Pellets were counted and resuspended in complete media at a concentration of 2 
million cells/mL. 
Standard FAIRE 
 FAIRE was performed as previously described.12 In brief, BMDMs were fixed with 
formaldehyde followed by lysis with freshly made buffer (10 mM Tris-HCl pH 8.0, 2% Triton X-
100, 1% SDS, 100 mM NaCl, 1 mM EDTA). DNA was sonicated into 300-500 length base pair 
(BP) fragments. DNA was treated with RNase followed by PCIA extraction to isolate nucleosome-
free DNA, found in the aqueous phase of the extraction. DNA was precipitated using ice cold 
100% ethanol with a 1:10 volume of 3M NaOAc, 20µg of glycogen, and incubated at -80°C for 
30 minutes. DNA pellets were spun down, washed with ice cold 70% ethanol, and dried to remove 
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excess ethanol. Pellets were resuspended in 10mM Tris-HCl. DNA was quantified using the Qubit 
High Sensitivity Assay Kit (Thermo Fisher Scientific). 
Standard qRT-PCR 
 qRT-PCR reactions were prepared using 1ng of DNA, 10µg, of forward and reverse 
primers, 10µL PowerUp SYBR Green Select Master Mix (Thermo Fisher Scientific CAT# 
1710042) and brought up with dH2O for a final reaction volume of 20µL. Fold changes for the 
readout were calculated by the equation: 
 
 
Table 1. Primer sequences used for qRT-PCR 
Primer Forward (5’->3’) Reverse (5’->3’) 
Suz12 TTCAAAGAGGCGTCCGGG CAGAGTCCCCCGTCAGTCAC 
Steap3 GTAACTGGGACACCTCCCCT GGGCACTCTCTAACCGAACA 
Leprot GGCAGGGATCAGAACCAGTAT TCTGCCAATTACAACCTCACAC 
Cacng8 AGGCCATGTTTGGGATACTG AAAGCAGAAGCGGAACTCAC 
Il6 CCCAATTTCCAATGCTCTCCT  GTCTTGGTCCTTAGCCACTCC  







Small molecule screen with HT-FAIRE readout 
 Mature BMDMs were seeded at a density of 200K cells/well and treated with 1μM of each 
individual compound (n=62) or DMSO and were incubated for 16 hours. Samples were fixed with 
1% formaldehyde in the 96-well plate followed by lysis with fresh buffer. Samples were sonicated 
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in the plate (SonicMan; Matrical BioScience) followed by treatment with RNase. DNA Cleanup 
was done using a 96-ChIP DNA silica matrix clean and concentrator column (D5207; Zymo 
Research). qRT-PCR reactions were done in 384-well plates using 2µL of FAIRE DNA, 0.1 µL 
of primer(50 µM), and 5µL of PowerUp SYBR Green Master Mix (Thermo Fisher Scientific 
CAT# 1710042) as previously described.13 Changes in chromatin accessibility were quantified the 
using a predefined calculation for “relative chromatin inhibition” (RCI) score.  This equation is 
graphically shown below: 
 
 
Figure 2. Graphical representation of screen calculations. 
 
 
JQ-1 Challenge/RNA isolation 
 Isolated BMDMs were cultured for seven days as described above. Macrophages, at a 
concentration of 5 M/mL were co-incubated with either; (+)-JQ1, or its enantiomer (-)-JQ1 and 
lipopolysaccharide (LPS 10uL/mL). After sixteen hours, cells were lysed with 750uL TRIzol, at 
which point RNA was collected for further analysis via RT-qPCR. RNA was isolated utilizing 
Norgen Total RNA Purification Kit #37500, 250uL of Chloroform were added to the TRIzol-
sample mixture and vortexed. At 4°C, samples were centrifuged for 10-12 minutes at 13-14K rpm. 
Following centrifugation, up to 600uL of the aqueous layer was removed and added to 500uL of 
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70% EtOH. The EtOH-sample mixture was then added to RNA isolation columns and centrifuged 
at room temperature for 1 min at 6K rpm and flow through was discarded. Columns were purified 
using 400uL of wash buffer, which was then centrifuged for 1 min at 6K rpm. RNA was eluted in 
20-30uL using Norgen elution buffer. Concentration was determined using Thermo Scientific 
Nanodrop 2000c Spectrophotometer.  
Making cDNA 
 cDNA was made, using Applied BioSystems’ High Capacity cDNA Reverse Transcription 
Kit (Cat #4368814). Each reaction contained, 9 uL of “working stock”, 1uL Reverse Transcriptase 
enzyme and 10uL of RNA sample. “Working stock,” contains 100uL of 10x Reverse Transcriptase 
Buffer, 40uL of 100mM dNTPs, 100uL of 10x Random Primers and 210uL of Nuclease free water. 
Following pulse centrifugation, samples were subjected to three cycles of temperature regulation, 
Cycle 1, 25°C for 10 min, Cycle 2, 37°C for 120 min, and 85°C for 5 min. Samples were then 
stored at 10°C until RT-qPCR could be performed. 
Current JQ-1 Challenge 
 BMDMs were cultured and raised for seven days. Macrophages at a concentration of 5 
M/mL were first incubated with JQ-1(+), or its negative enantiomer JQ-1 (-). After the initial 
twelve hour incubation cytokines IFN-g, IL-4, or IL-10 were added, so that macrophages were 
then co-incubated with JQ-1(+/-) and a cytokine for an additional four hours. After four hours, 








 The formula for Real Time Quantitative Polymerase Chain Reaction was as follows: a hold 
stage consisting of two min at 55°C and two min at 95°C, then forty cycles of measured 
amplification; the first stage at 95°C for 30 seconds, the second stage at 60°C for 30 seconds and 
the final stage at 72°C for 30 seconds. A hold stage at 72°C for 10 min was run after the completion 
of the PCR cycles and a standard melt curve was run. 
 
RESULTS 
 Chromatin modifying enzymes are known for their ability to alter chromatin accessibility. 
Our experiment aimed to address whether specific chromatin modifying compounds could 
selectively alter the chromatin accessibility at IL10VARs. 
 In order to perform this HT-screen, we needed to identify IL10VARs as well as positive 
and negative controls (Figure 3). A positive control is a gene that is accessible in both WT and 
Il10-/- mice and a negative control is a gene that is not accessible in either mice model. It is 
important to have regions that are equally accessible so that the IL10VARs, regions that differ in 
WT and Il10-/- mice, can be quantitatively compared to regions that were unchanged. Leprot was 
a good candidate as a positive control as it is a region of accessible chromatin in both WT and IL-
10 deficient mice. CACNG8 serves as a negative control since the chromatin region was neither 
accessible in WT nor IL-10 deficient mice. To confirm the status at these loci, we performed 
standard FAIRE-qPCR on macrophages from WT and Il10-/- mice and determined the calculated 
fold changes. High calculated fold change values in Figure 3 indicate increased accessibility in 
these chromatin regions, while low calculated fold changes indicate a region of chromatin that was 
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less accessible. This indicates that Suz12 and Steap3 are IL10VARs and have a chromatin profiles 




Figure 3. Preliminary IL10VAR confirmation 
Standard FAIRE qRT-PCR demonstrated that Suz12 and Steap3 regions possessed a closed 
chromatin accessibility in WT mice as compared to Il10-/- mice.  Controls Leprot (positive) and 
Cacgn8 (negative) are essential as they are used as controls for the calculated fold change. n=2. 
 
To determine the ability of small molecules to alter chromatin accessibility, we performed 
a screen with a HT-FAIRE-qPCR readout and calculated the RCI score for treatment with each 
compound. Our findings revealed 35 small molecules were able alter chromatin accessibility by 
more than two standard deviations below the DMSO control. This list of “hits” included several 
different classes of inhibitors (eg. Inhibitors of bromodomains and histone methyltransferases) and 




Figure 4. Chromatin modifying enzymes alter gene expression in CD mouse models 
Log2 ratio of the RCI values plotted against the rank order of compounds from greatest relative 
decrease (top, left side of x-axis) to greatest relative increase (top, right side of axis) in FAIRE 
signal. The black line indicates the significance cutoff of RCI values ≥2 SDs or ≤2 SDs from the 
average RCI for DMSO controls. Compounds that show the greatest decrease in FAIRE signal are 





In order to narrow this list, practical considerations were made for compounds that had 
been previously tested in cells (Table 2).  Considerations included the compound’s ability to 
suppress inflammation and if any had been specifically tested in macrophages or in vivo. The small 
molecules that are highlighted in red in Figure 4 are the refined list of compounds; interestingly 
all seven are bromodomain inhibitors. Bromodomain proteins are responsible for recognizing 
acetylated lysine residues on histone tails. The recognition of these acetyl-lysines results in the 
recruitment of other chromatin modifying factors or the recruitment of transcription factors which 
will promote gene expression.13 Previous literature has shown the majority of these compounds 
are nontoxic to cells, can prevent inflammation, and some have been tested in BMDMs, including 
the well-characterized BET-family inhibitor (+)-JQ1.14 
Table 2. Compound classification and effects on cells18-25 
 
 After analyzing the practical considerations derived from Table 2, including the compound 
being non-toxic to cells and having been studied in macrophages previously, we chose (+)-JQ1 for 
further testing. (+)-JQ1 has been shown to alter chromatin accessibility; however, while the 
negative enantiomer (-)-JQ1 is unable to do so.18 Because of this, we used (-)-JQ1 as an additional 




Figure 5. Level of mRNA Il6 cytokine levels following (+)-JQ1/LPS Challenge  
 (Left) Attenuation of Il6 mRNA expression levels is observed in both wild-type and  
Il10-/- macrophages treated with (+)-JQ1 during LPS challenge. (Right) Calculated proportional 
inflammation reduction (stimulation and treatment normalized to stimulation, alone) demonstrates 
that (+)-JQ1 treatment decreases Il6 expression levels in a dose dependent manner. 1µM treatment 
results in Il6 expression levels that are 20% of the total amount expressed by untreated, stimulated 










Figure 6. Levels of mRNA IL-12 cytokine levels following (+)-JQ1/LPS Challenge 
 (Left) Attenuation of Il12ß mRNA expression levels is observed in Il10-/- macrophages 
treated with (+)-JQ1 during LPS challenge, but not wild-type macrophages. (Right) Calculated 
proportional inflammation reduction (stimulation and treatment normalized to stimulation, alone) 
demonstrates that (+)-JQ1 treatment of stimulated Il10-/- macrophages results in Il12ß expression 
levels that are 30-35% of the total amount expressed by untreated, stimulated cells, regardless of 
dose. Treatment of wild-type macrophages results in increased Il12ß expression, regardless of 
dose. 
DISCUSSION 
The increase in prevalence of CD over recent decades, and lack of an available long-term 
treatment has drawn increased attention to the biological mechanisms that underlie the disease. 
Despite advances, further experiments can aid in the understanding of macrophages, key to the 
human innate immune system and CD presentation. We pursued this experiment of macrophages 
for two main reasons. First, the chromatin profile resulting from IL-10 deficiency is stable as less 
than 5% of IL10VARs decrease in accessibility when exogenous IL-10 is added back to Il10-/- 
macrophages.4 Additionally, IL-10 therapeutic drugs have failed to provide relief in the clinic for 
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CD patients, and IL-10 is not a known chromatin regulator.15 This indicates the importance of a 
finding a different method to alter the chromatin accessibility in macrophages, which may have 
therapeutic impact. 
In order to prepare for a small molecule screen of compounds to alter chromatin 
accessibility, we first needed verify IL10VARs. We confirmed Suz12 and Steap3 are differentially 
accessible chromatin in WT and Il10-/- mice. Our positive control, Leprot, showed increased 
accessibility to the same degree in both the WT and Il10-/-. The negative control, Cacgn8, showed 
decreased accessibility in both conditions.  With this information, we proceeded to our screen, 
which tested the ability of 62 different small molecule inhibitors of chromatin modifying proteins 
to alter the chromatin profile at the confirmed IL10VARs, Suz12 and Steap3. We found that 35 
different small molecules were able to decrease chromatin accessibility at these IL10VARs. These 
results are the early stages of providing another method to alter the chromatin profile at different 
loci of Il10-/- macrophages. 
Our standard for “hits” was RCI scores that were greater than two standard deviations 
below the DMSO control RCI scores. To refine the list of 35 hits, we investigated previously 
published literature and found that bromodomain inhibitors have anti-inflammatory properties and 
some have been studied in macrophages. Seven of the 35 hits, listed in Table 2, and highlighted in 
red in Figure 4, were selected based on these previous findings. We chose these seven compounds 
for further research because they are non-toxic to cells and either have known anti-inflammatory 
properties or have been previously tested in macrophages. 
For follow up experiments, these screen results need to be confirmed using traditional 
FAIRE-qPCR analysis. While high-throughput methods are useful for identifying potential small 
molecules of interest, the standard FAIRE assay produces a more robust signal.14 Second, this 
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screen examines chromatin alterations at two specific loci. We ideally would like to examine the 
abilities of these bromodomain inhibitors across the genome. Regions that contain regulatory 
elements that promote expression of inflammatory genes would be of particular interest, since 
expression of inflammatory genes is a key component in CD pathogenesis.  To examine the ability 
of these compounds to prevent expression of inflammatory genes, we can test for the presence of 
IL-12β, a subunit of both the IL-23 and IL-12 cytokines. In a follow-up experiment, macrophages 
can be treated with different chromatin modifying enzymes and then later stimulated with LPS. 
Using qPCR we can quantitative determine the level of IL-12β expression, a marker we will use 
for inflammation. 
Following the screen we performed follow-up experiments using (+)-JQ1. We generated 
BMDMs from both WT and Il10-/- mice. Mature BMDMs were either incubated with the positive 
or negative enantiomer of JQ1 (the negative enantiomer is inactive and therefore serves as a 
negative control).16 Treated cells were also incubated with either LPS or absence of LPS. This 
gives an experiment with four conditions. Samples were incubated for four hours and cells were 
fixed for FAIRE and extracted for RNA. The supernatant was saved in this experiment, and 
following the results from the RNA obtained and the subsequent cDNA qPCR readout, the 
supernatant can be examined to see what cytokines were secreted by the cells during incubation. 
 The first secreted cytokine that we examined in further detail was Il6. As hypothesized, 
cells incubated with (-)-JQ1 and without LPS showed little expression of the pro-inflammatory 
cytokine Il6. This sample served as our non-stimulated, non-treated control.  The next condition 
examined for Il6 cytokine levels was (-)-JQ1, but with LPS. In both the WT and Il10-/- mice this 
experimental condition had the greatest level of the cytokine Il6. The crucial part to Figure 5, is 
the comparison of these levels to the levels of the condition (+)-JQ1 and LPS. Both conditions 
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were stimulated with LPS, but the fourth experimental condition was also co-incubated with the 
active JQ1 enantiomer. Because of the ability of this enantiomer to alter chromatin accessibility, 
much less levels of the mRNA transcript for the proinflammatory cytokine Il6 were recorded. This 
was consistent across both the WT and Il10-/- mice. Additionally, the effects of (+)-JQ1 incubation 
were dose dependent. Figure 5 (right) depicts that while 200nM of (+)-JQ1 lessened the 
proinflammatory cytokine secretion of Il6 by 40-50% in both the WT and Il10-/- models, cells 
incubated with 1000nM of JQ1, had levels of proinflammatory cytokine secretion only 20% of 
their untreated, but stimulated with LPS counterparts. In summary, (+)-JQ1 attenuated 
proinflammatory cytokine secretion of Il6, in a dose dependent manner, in both WT and Il10-/- 
mice. 
In addition to Il6 cytokine levels, we also examined the levels of Il12ß. Like the levels of 
Il6, when comparing the untreated-unstimulated control, to the untreated-stimulated group, the 
latter experienced much greater levels of Il12ß. While this comparison mirrors the results of the 
Il6 cytokine levels, when comparing these levels to the stimulated-treated experimental cells a 
clear difference arises. Like before the addition of (+)-JQ1 in Il10-/- models attenuated 
inflammation when comparing the presence or absence of (+)-JQ1, yet in the WT mice, the levels 
of Il12ß were greater in the treated experimental group than in the untreated controls. This was 
contrary to the previous results presented. To explain this phenomenon, we have a supplementary 
hypothesis. IL-10 is a regulator of Il12ß, so in the Il10-/- mice we expect the inherent levels of 
Il12ß to much greater than in the WT mice. Furthermore, (+)-JQ1 decreases Il10 expression which 
would theoretically increase Il12ß expression. In the KO mice, this effect is nominal because the 
inherent Il12ß is very high, but in the WT mice, this addition of (+)-JQ1, could account for the 
increased Il12ß levels. 
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While the results of this project are ongoing, the results may be applicable for the treatment 
of disease. We have demonstrated that in regions that are unchanged with the addition of ectopic 
IL-10 can be altered with chromatin modifying proteins and subsequently attenuate pro-
inflammatory cytokine secretion in both WT and Il10-/- models. As we continue to investigate (+)-
JQ1 and other small chromatin modifying proteins, we will explore the ability of compounds to 
alter chromatin accessibility, and subsequently cytokines necessary for macrophage 
differentiation. With continuing promising results, these compounds may serve as the basis for 
targeted drug therapy of inflammatory diseases. 
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Table 3. Epi-G Diamond Set Compounds 
Compound Name Target Class Protein Target(s) 
 
 
(+)-JQ1 bromodomain BET family 
 
PFI-1 bromodomain BET family 
 
GSK2801 bromodomain BAZ2A/B 
 
BAZ2-ICR bromodomain BAZ2A/B 
 
I-CBP112 bromodomain CREBBP/EP300 
 
SGC-CBP30 bromodomain CREBBP/EP300 
 
PFI-3 bromodomain SMARCA2/4, PBI(5) 
 
OF-1 bromodomain BRPF family 
 
NI-57 bromodomain BRPF family 
 
PFI-4 bromodomain BRPF1 
 
LP99 bromodomain BRD9/7 
 
BI-9564 bromodomain BRD9/7 
 
I-BRD9 bromodomain BRD9 
 
Bromosporine bromodomain bromodomains 
 
I-BET762 (GSK525762A) bromodomain BET family 
 
I-BET151 bromodomain BET family 
 
OTX015 bromodomain BET family 
 
Cl-994 (Tacedinaline) HDAC HDAC1,2,3 
 
LAQ824 (Dacinostat) HDAC HDACs 
 
TSA HDAC HDACs (except 8) 
 




CAY10603 HDAC HDAC6 
 
PCI-34051 HDAC HDAC8 
 
Romidepsin HDAC HDACs 
 
Chidamide HDAC HDACs 
 
Panobinostat HDAC HDACs 
 
Entinostat HDAC HDAC1,3 
 
UNC0638 HMT G9a/GLP 
 
A-366 HMT G9a/GLP 
 
UNC0642 HMT G9a/GLP 
 
UNC1999 HMT EZH2/EZH1 
 
EPZ-6438 HMT EZH2 
 
GSK343 HMT EZH2 
 
GSK126 HMT EZH2 
 
EI1 HMT EZH2 
 
EPZ011989 HMT EZH2 
 
SGC0946 HMT DOT1L 
 
EPZ-5676 HMT DOT1L 
 
(R)-PFI-2 HMT SETD7 
 
LLY-507 HMT SMYD2 
 
BAY-598 HMT SMYD2 
 
SGC707 HMT PRMT3 
 
EPZ015666 HMT PRMT5 
 
A-196 HMT SUV420H1/H2 
 
GSK591 HMT PRMT5 
 




MS049 HMT PRMT 4&6 
 
UNC1215 Kme Reader L3MBTL3 
 
OICR9429 Kme Reader WDR5 
 
UNC3866 Kme Reader CBX4/7 (CBXs) 
 
GSK-J4 (J1) Demethylase JMJD3/UTX 
 
GSK-LSD1 Demethylase LSD1 
 
HCl-2509 (SP2509) Demethylase LSD1 
 
KDOAM25 Demethylase JARID1/KDM5 
 
IOX2 Other PHD (Prolyl hydroxylase) 
 
GSK484 Other PAD-4 (Protein Arg deiminase 4) 
 
IOX1 Other 2-OG (OxoGlutarate oxygenases) 
 
C646 Other p300 (HAT) 
 
Olaparib Other PARP (poly ADP ribose polymerase) 
 
Decitabine Other DNMTs 
 
PTC-209 Other BMI-1 
 




 All of the above data would not have been possible without the help from specific people 
and funding from specific sources. All of the above work has been conducted under the supervision 
and in conjunction with Michelle Hoffner O’Conner and the Sheikh lab manager Matthew R. 
Schaner. I have also been heavily mentored by Dr. Shehzad Sheikh, and my biology advisor, Dr. 
Terrance Furey. Without all of their help and support, this work would not have been possible. 
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